TrialReader


Chronic Heart Failure - COngestion eValuation

NCT05089149 — Not applicable, Recruiting, 200 participants, Pr. Nicolas GIRERD

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique. CHF-COV (Chronic Heart Failure - COngestion eValuation)

RegistryNCT05089149, acronym CHF-COV
StatusRecruiting
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, diagnostic
Enrollment200 (Estimated)
SponsorPr. Nicolas GIRERD (Other)
ConditionsChronic Heart Failure
InterventionsClinical examination centered on congestion, Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography, Blood sample retrieved for biological assessment and biobanking, Telephone follow-up, Kansas City Cardiomyopathy Questionnaire (KCCQ) (Procedure, other, behavioral)
Datesstart 2021-12-14, primary completion 2028-12-14 (estimated), completion 2029-06-14 (estimated), first posted 2021-10-22, last updated 2023-06-05
Locations2 sites in France

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Chronic Heart Failure All trials of Clinical examination centered on congestion All trials of Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography

-Summary

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.

The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Patients with chronic heart failure coming for scheduled day hospitalizationExperimentalProcedure: Clinical examination centered on congestion; Procedure: Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography; Procedure: Blood sample retrieved for biological assessment and biobanking; Other: Telephone follow-up; Behavioral: Kansas City Cardiomyopathy Questionnaire (KCCQ)* Clinical examination focusing on congestion * Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds * Blood sample retrieved for biological assessment and biobanking * Telephone follow-up
  • Clinical examination centered on congestion (Procedure): Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
  • Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography (Procedure): Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
  • Blood sample retrieved for biological assessment and biobanking (Procedure): Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
  • Telephone follow-up (Other): Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
  • Kansas City Cardiomyopathy Questionnaire (KCCQ) (Behavioral): Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge

+Outcome measures

Primary outcomes

  • Rate of death from all causes [24 months after day hospitalization or consultation]: composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 2)
  • Rate of hospitalisation for acute heart failure [24 months after day hospitalization or consultation]: composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 1)

Secondary outcomes

  • Rate of death from all causes [24 months after day hospitalization or consultation]
  • Rate of hospitalisation for acute heart failure [24 months after day hospitalization or consultation]
  • Rate of hospitalisation for cardiovascular reason [24 months after day hospitalization or consultation]
  • Rate of death from all causes [24 months after day hospitalization or consultation]: composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 7)
  • Rate of hospitalisation for acute heart failure [24 months after day hospitalization or consultation]: composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 6)
  • Rate of cardiovascular death [24 months after day hospitalization or consultation]
  • NYHA (New York Heart Association) class measured [3, 12 and 24 months after day hospitalization or consulation]
  • Natriuretic peptides [At inclusion]: BNP or Nt-Pro BNP
  • Renal function assessed by glomerular filtration rate [At inclusion]
  • Plasma volume [At inclusion]: Calculated from haemoglobin and haematocrit value
  • Rate of Bilirubin [At inclusion]
  • Rate of ASAT [At inclusion]
  • Rate of ALAT [At inclusion]
  • Rate of V factor [At inclusion]
  • Blood potassium concentration [At inclusion]
  • Liver elastography value [At inclusion]: Measured with Fibroscan®
  • Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ) [At inclusion and 3, 6 and 24 months]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients with chronic acute heart failure admitted in hospital for scheduled day hospitalization or consultation
* Age ≥18 years
* Patients having received complete information regarding the study design and having signed their informed consent form.
* Patient affiliated to or beneficiary of a social security scheme.

Exclusion Criteria:

* Comorbidity for which the life expectancy is ≤ 3 months
* Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate <15 ml/min/m2 at inclusion.
* History of lobectomy or pneumonectomy lung surgery
* Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.
* Pregnant woman, parturient or nursing mother
* Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
* Adult person who is unable to give consent
* Person deprived of liberty by a judicial or administrative decision,
* Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.

+Locations (2)

FacilityCityCountryStatus
CHRU de NancyVandœuvre-lès-NancyFranceRecruiting
CHRU de NancyVandœuvre-lès-NancyFranceNot yet recruiting

My Notes